Category: Medical

The global healthcare data monetization solutions market size was calculated at USD 921.04 million in 2024 and is predicted to reach around USD 4,077.14 million by 2034, expanding at a CAGR of 16.04% from 2025 to 2034. The growing need to leverage patient information, medical records, and clinical insights, which help generate revenue or value for healthcare organizations, is increasing the demand for the healthcare data monetization solutions market.

How is Artificial Intelligence (AI) changing the healthcare data monetization solutions market?
Integration of artificial intelligence in the healthcare data monetization solutions market has the potential to bring advanced technology. Along with that, healthcare is becoming a data-driven industry. AI is anticipated to play a crucial role in data monetization by providing personalized medicine, improving operational efficiency, bring preventative care programs and collaborative partnerships. These advancements are expected to leverage healthcare data by improving patient care and bringing innovations. Additionally, AI can also used to support digital communication, offer schedule reminders, design help tips, and suggest next steps to patients. These characteristics of AI will help with better diagnosis and improve the speed and accuracy of patient visits, resulting in faster and more personalized care.

US healthcare data monetization solutions market size and growth 2025 to 2034
The US healthcare data monetization solutions market size was exhibited at USD 309.47 million in 2024 and is projected to be worth around USD 1,394.89 million by 2034, growing at a CAGR of 16.25% from 2025 to 2034.

North America dominated the global healthcare data monetization solutions market in 2024S, owing to the advanced healthcare infrastructure and investment in technology. The American Hospital Association reports 1887 hospital mergers in the past decade, contributing to reshaping the U.S. healthcare industry. The Centers for Medicare and Medicaid Services (CMS) provide data as a means to enable researchers and policymakers to gain deeper insights into how mergers, acquisitions, consolidation, and changes of ownership affect access to care, cost, and quality. The main healthcare system notices in the U.S. and Western society include the Beveridge model, the Bismarck model, the national health insurance model, and the out-of-pocket model.

Europe is anticipated to grow at the fastest CAGR in the healthcare data monetization solutions market during the projected period due to supportive government policies and increasing awareness regarding the growing opportunities of data monetization. With digital adoption, the region’s government has implemented a regulatory system. The region has benefited from data generation in formulating various acts and policies throughout the states, incorporating data protection, data security, data privacy, and data sharing to reduce the risk of cyber threats and other branches. The government establishes various processes to enhance collaboration and flow data to improve the industry ecosystem.

Market dynamics
Driver
Real-world evidence
Rising demand for real-world evidence in the healthcare industry is proliferating the growth of the healthcare data monetization solutions market. Real-world data is a set of information on a patient’s health status and the delivery of a healthcare routine, which is collected from a variety of sources. Real-world data (RWE) includes data collected from electronic health records, medical claims data, data from product or disease registries, and many more. This is proven evidence about the usage and potential benefits or risks of a medical product derived from a studied RWE, understanding drugs, and routine clinical practice. RWE helps to provide a deeper understanding of how interventions perform on diverse patient populations, assess the cost and effectiveness of treatment, monitor for side effects, and provide data on rare diseases. Moreover, this revolutionized help in the healthcare industry in drug development.

Restraint
Risks associated with healthcare data
As healthcare data is extremely sensitive, a breach in the data can lead to loss of reputation, cost lawsuits, and patient privacy will be exposed. The healthcare data monetization solutions market holds the sole responsibility to protect the collected data, aggregates, and potentially shares. This data represents a significant accountability for both security and legal terms. Therefore, direct monetization requires careful analysis of the risks, benefits, and actions of monetizing special medical data.

Opportunity
Personalized medicine and genomics
The future of the healthcare data monetization solutions market is anticipated to bring immense promise for transforming the deliverance and experience of healthcare. Personalized medicine is constantly evolving in the healthcare industry, and it uses patients’ genetic profiles to make medical decisions. Genomics is a main component of personalized medicine. The application of these technologies in data monetization is expected to enhance the understanding of disease and its molecular mechanisms, resulting in enhancing the capacity of personalized interventions. Personalized genomic medicines have the potential to classify complex diseases and discover more specific treatments based on genomics.

Type insights
The indirect data monetization segment contributed the highest share of the healthcare data monetization solutions market in 2024. The dominance of this segment is observed as the data does not leave the organization. It is used to build better-personalized healthcare plans for patients and digitally empower the patient to take an active part in their health and wellbeing. The indirect data monetization approach in the healthcare industry uses analytics to get valuable insights to enhance internal processing, products, and services.

The direct data monetization segment is anticipated to grow at the fastest CAGR from 2025 to 2034. The growth of this segment is experienced as this helps in building revenue streams by selling data to third parties, setting up data-as-a-service, or creating personalized products and services for key demographics with partners. Several pharmaceutical companies are launching schemes to share research data which will be helpful in transforming diagnosis and development of customized medicines.

Facility size insights
The large facilities segment captured the biggest share of the healthcare data monetization solutions market in 2024. This segment deals with the key leaders in the healthcare industry, such as academic medical centers and major hospitals. These facilities offer resources to invest in advanced data monetization solutions, which help with obtaining knowledge that is used in complex analytics, artificial intelligence, and data processing tools. In addition, it helps support research and collaboration with other stakeholders in the healthcare landscape.

On the other hand, the small and medium facilities segment is anticipated to grow at a significant CAGR during the forecast period. The increasing adoption of healthcare data monetization in small & medium facilities is observed as it improves operation efficacy using real-time data, generates revenue streams by selling data as a service, collaborates with larger entities, adopts new technologies, and meets customer needs.

End-use insights
The healthcare payers segment captured the biggest share of the healthcare data monetization solutions market in 2024. The dominance of this segment is noticed as healthcare payer such as health insurers are driving forces in the healthcare ecosystem and adapting to data monetization to improve the value of healthcare and accessibility for their member. Healthcare payers use patient records for research, personalized medicine, and improving patient outcomes. It has also contributed to population health management by identifying at-risk patients and developing target interventions to improve their health results.

The life science companies segment is expected to grow rapidly during the forecast period. The growth of this segment is observed as life science companies play a vital role in the healthcare industry through research and development and manufacturing of products and technologies that help to improve health outcomes. Life science companies include biotechnology experts, medical device developers, and pharmaceutical manufacturers. The key role in the healthcare industry is to provide a possible treatment, cure the patient, and provide health-related benefits such as death claims and life insurance policies. Precedence Research

Healthcare spending in the United States reached $4.9 trillion and increased 7.5% in 2023, according to a study published online Dec. 18 in Health Affairs.

Anne B. Martin, from the Centers for Medicare & Medicaid Services in Baltimore, and colleagues examined growth in national health expenditures in 2023.

The researchers found that in 2023, healthcare spending in the United States reached $4.9 trillion and increased 7.5%, up from a rate of 4.6% in 2022. The insured share of the population reached 92.5% in 2023, as enrollment in private health insurance increased strongly for the second year running; private health insurance and Medicare spending both grew faster than in 2022. As the Covid-19 public health emergency ended, spending and enrollment growth slowed for Medicaid. The health sector’s share of the economy was 17.6% in 2023, which was similar to 17.4% in 2022, but lower than the share in 2020 and 2021 during the height of the pandemic. Compared with 2022, in 2023, state and local governments accounted for a higher share of spending, while the federal government share was lower with the decline in Covid-19-related funding and slowing in growth of federal Medicaid spending.

“On average during 2020 to 2023, healthcare spending and overall economic growth increased 6.6% and 6.5% per year, respectively,” the authors write. “As a result, the share of the economy devoted to healthcare in 2023 (17.6%) was about the same share as in 2019 (17.5%).” HealthDay

The government on Saturday said that Prime Minister Narendra Modi inaugurated, laid the foundation stone and dedicated 28 key projects worth Rs 3,921 crore under the Employees’ State Insurance Corporation (ESIC) this year.

In 2024, ESIC also gave in-principal approval for the establishment of 10 new ESIC medical colleges at Andheri (Maharashtra), Basaidarapur (Delhi), Guwahati- Beltola (Assam), Indore (Madhya Pradesh), Jaipur (Rajasthan), Ludhiana (Punjab), Naroda-Bapunagar (Gujarat), Noida and Varanasi (Uttar Pradesh) and Ranchi (Jharkhand).

ESIC has approved the set up for 97 new ESI hospitals across the country in the last 10 years. To provide the access to quality medical care across the country, ESIC is in process of convergence with Ayushman Bharat- Pradhan Mantri Jan Arogya Yojana (AB-PMJAY).

This will benefit over 14.43 crore ESI beneficiaries and their families. ESIC beneficiaries will be able to avail secondary and tertiary services at over 30,000 AB-PMJAY-empanelled hospitals, with no financial ceilings on treatment costs, said the Ministry of Labour and Employment.

In October, as many as 17.80 lakh new employees were enrolled under the ESIC scheme. The year-on-year analysis showed a growth of 3 per cent in net registrations compared to October last year.

Out of the total 17.80 lakh employees added during the month, 8.50 lakh employees amounting to around 47.75 per cent of the total registrations belonged to the age group of up to 25 years. The gender-wise analysis of the payroll data indicated that the net enrolment of female members was 3.52 lakh in October.

According to the government, the ESI scheme currently offers medical care under 165 hospitals, 1,590 dispensaries, 105 dispensary-cum-branch-offices (DCBOs), and around 2,900 empanelled private hospitals. In the last 10 years, the ESI scheme has been implemented in 687 districts out of 788 districts of the country, from the 393 districts in 2014. Free Press Journal

Chennai’s top quaternary care multi-speciality hospital, Gleneagles Hospital Chennai honoured with Sanjeevani Healthcare Excellence Award for excellence in Surgical Oncology. The Award was presented to Prof. Dr S Rajasundaram at The Third edition of India Heals “SANJEEVANI 2024” An International Event (Exhibition cum Conference) on Healthcare and Wellness, organized and supported by the Department of Commerce, Ministry of Commerce and Industry, Government of India in partnership with the Services Exports Promotion Council (SEPC) held in New Delhi recently.

Dr Rajasundaram, Head of Surgical Oncology at Gleneagles Hospital Chennai, expressed gratitude upon receiving the award. “The Surgical Oncology department at Gleneagles Hospital Chennai is equipped with state-of-the-art technology and staffed by a multidisciplinary team of highly skilled oncologists, surgeons, and support staff. The hospital’s patient-centric approach, coupled with innovative surgical techniques, ensures exceptional outcomes for individuals battling cancer. This recognition is a testament to the dedication of our team and our commitment to offering the highest standards of cancer care. We are honoured to be acknowledged by the Sanjeevani Healthcare Excellence Awards, and we will continue to push boundaries in surgical oncology to improve patient outcomes.”

“I am incredibly proud of our Oncology department for this outstanding achievement. Sanjeevani Healthcare Excellence Award recognizes the hospital’s unwavering commitment to advancing cancer treatment and providing world-class care to its patients. Congratulations to the entire team for this well-deserved recognition” said Dr Nageshwar Rao, CEO, Gleneagles Hospital Chennai. Passionate In Marketing

Three officials linked to the Pradhan Mantri Jan Arogya Yojana (PM-JAY) were arrested by the Ahmedabad Crime Branch for issuing illegal Ayushman cards. Dr Shailesh Anand, a medical officer working for PM-JAY under the Health department, a staff member who approved surgeries online using PM-JAY’s data, and Nikhil Parekh, the digital head of the company handling PM-JAY-related work were arrested for their dubious role in the scheme. .

The investigation found that suspect Ayushman cards were being used to approve surgeries under PM-JAY. Dr Anand, along with Milap Patel (a project officer at the Health department), and Parekh, were directly involved. They had been illegally issuing Ayushman cards using data from the PM-JAY database, allowing surgeries to be approved for individuals who were not eligible.

The Ahmedabad Crime Branch uncovered details while investigating the Khyati hospital scam. The investigation pointed to the involvement of employees from the Health department’s PM-JAY team, particularly Dr Anand.

Dr Anand, who was associated with Khyati hospital and knew Chirag Rajput, played a central role in this fraud. He was coordinating with Patel to match the fake Ayushman cards with eligible beneficiaries, charging ₹2,000 to ₹3,000 per card.

Dr Anand was not only involved with Khyati hospital, but also attempted to profit from this scam at other hospitals. He had instructed Patel to join various WhatsApp groups with agents.

Through these channels, they were able to approve surgeries by falsely matching cards with beneficiaries at an 80% match rate. Preliminary investigations revealed that Dr Anand had matched over 4,000 Ayushman cards using this illegal method. GujaratSamachar

The Middle East is undergoing a significant transformation in healthcare, driven by the adoption of Electronic Health Records (EHR), population health management tools, and AI technologies. Governments in the UAE, Saudi Arabia, Qatar, and Oman are leading these digital healthcare initiatives, driven by national frameworks such as Vision 2021, Vision 2030, and Health Vision 2050. However, despite these ambitious goals, the region faces ongoing challenges, such as issues with interoperability, data standardization, and workforce readiness, which need to be addressed to fully realize the potential of these emerging technologies.

Across the GCC (Gulf Cooperation Council, a political and economic alliance of six countries in the Arabian Gulf region), over 75% of public healthcare facilities have implemented EHR systems, providing the foundation for broader digital transformation. These systems are being enhanced with advanced analytics, decision support tools, and predictive care models to drive population health insights. One of the key focuses of these developments is improving interoperability – creating unified health information exchanges (HIEs) that facilitate data sharing between the public and private sectors. Furthermore, cloud-based EHR platforms are being used to improve scalability and operational efficiency, particularly benefiting smaller healthcare systems in countries such as Qatar and Bahrain.

As the healthcare IT market in the Middle East is projected to grow at a CAGR of 9.2%, reaching $7.9 billion by 2028, several key trends are driving this growth.

These trends include:
Population health management: Advanced analytics platforms are enabling healthcare systems to aggregate large datasets, identify emerging trends, and predict risks for proactive disease management. In Qatar, the Ministry of Public Health is utilizing population health management tools to monitor chronic diseases and improve care coordination across the country, aligning with the Qatar National Health Strategy (NHS).

Clinical decision support: Integrated systems are providing real-time, evidence-based recommendations at the point of care, improving diagnostic accuracy and treatment outcomes. In the UAE, Cleveland Clinic Abu Dhabi uses Epic Systems’ decision support tools to enhance clinical workflows and provide real-time, evidence-based recommendations, improving diagnostic accuracy and patient outcomes.

AI-powered predictive analytics: Machine learning models are optimizing resource allocation, identifying patient risks, and personalizing care pathways, with a particular impact on chronic disease management. In Saudi Arabia, the Ministry of Health is integrating AI-powered analytics into its national health system to predict and manage the spread of chronic diseases, contributing to the goals of Saudi Vision 2030.

Blockchain for data security: Piloted in countries like Oman and the UAE, blockchain technology is being explored to ensure secure health information exchanges and robust data privacy. In Oman, blockchain technology is being tested to enhance healthcare data security, addressing privacy concerns in health information exchanges as part of the National Health Information System (NHIS).

Telehealth and EHR Integration: With the rise of telemedicine, seamless integration between telehealth platforms and EHR systems is expanding access to care and enabling remote monitoring and virtual consultations. Bahrain is integrating telemedicine services with its EHR systems to support virtual consultations and remote monitoring, improving access to healthcare in underserved areas.

Top vendors in the Middle East
Key players in the region’s healthcare digitalization include Epic Systems and Oracle Health, both of which are at the forefront of shaping the healthcare IT landscape. Epic Systems has earned high marks for its functionality, user-friendly interface, and seamless integration with advanced analytics platforms. Notably, Cleveland Clinic Abu Dhabi uses Epic’s systems to enhance care delivery, while Saudi Arabia’s Ministry of Health partners with InterSystems TrakCare to unify its health information systems. Oracle Health also plays a significant role, particularly in national health information systems such as Oman’s Ministry of Health platform. Oracle’s solutions are praised for their scalability and robust data security features, improving patient care efficiency and data integration across large-scale implementations. Hamad Medical Corporation in Qatar uses Oracle Health to manage chronic disease programs and monitor population health metrics.

Multinational EHR vendors need to consider the following regulations and frameworks as they expand their presence in the Middle East:

UAE: The Health Data Law governs the collection, storage, and sharing of patient data, and vendors must ensure compliance with stringent data protection standards. Additionally, Dubai Health Authority (DHA) mandates the adoption of EHR systems across healthcare facilities, with specific guidelines for integration with the city’s Health Information Exchange (HIE). The UAE’s focus on AI and data-driven healthcare initiatives also means that EHR vendors must align with these priorities.

Saudi Arabia: The country is rolling out the National Health Information Exchange (NHIE) to improve data sharing and integration. Vendors must ensure their platforms meet interoperability standards set by the NHIE. In alignment with Saudi Vision 2030, EHR vendors must also consider the country’s broader goals of making healthcare more accessible and efficient.

Qatar: As part of its National Health Strategy (NHS), Qatar is prioritizing digital health technologies, and EHR vendors must align with the standards set by the Supreme Council of Health (SCH). The country also emphasizes telemedicine integration, so vendors should ensure their platforms are capable of supporting remote monitoring and telehealth services.

Oman: Oman’s National Health Information System (NHIS) is based on Oracle Health’s platform, which provides the framework for health data integration across the country. Vendors entering the Omani market must ensure their systems are compatible with the existing infrastructure. Additionally, Oman is piloting blockchain technology to secure healthcare data, so incorporating blockchain into EHR and population health solutions will be crucial.

Bahrain: Vendors must adhere to the National Health Regulatory Authority (NHRA) guidelines, which govern healthcare data privacy. Bahrain is also working on national health data exchange initiatives, so vendors should focus on enabling interoperability and seamless integration with the country’s health networks.

Key challenges for multinational EHR vendors
Multinational vendors deploying EHR systems in the Middle East must address several key considerations. Compliance with regional data security and privacy laws, such as the Health Data Law in the UAE and NHIE in Saudi Arabia, is essential to ensure patient data remains secure. EHR systems must also be interoperable with national health information exchanges, particularly in countries like Saudi Arabia and Qatar, to enable seamless data sharing. With governments promoting AI-driven analytics for population health management, vendors should ensure their platforms are equipped with advanced AI tools that support these initiatives. Additionally, EHR systems must be adaptable to local languages and cultural needs, offering Arabic interfaces and aligning with each country’s healthcare goals. Finally, as the region transitions to more data-centric models, vendors offering user-friendly systems and comprehensive training will be critical to overcoming workforce readiness challenges.

“The Middle East is primed for a digital health revolution, with strong demand for AI-powered analytics, EHR systems, and population health tools,” said Doug Brown, President of Black Book. “Vendors who navigate local regulations, ensure data security, and adapt to regional digital health strategies will be key drivers in transforming healthcare across the region, despite challenges in workforce readiness and interoperability.” Black Book Research

Abbott Laboratories and DexCom said on Monday they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices.

The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Abbott and DexCom have accused each other of infringing certain patents multiple times over the years.

As part of the agreement, Abbott also granted DexCom a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and applications.
There are no financial payments associated with the settlement from either company. Reuters

Jefferies Equity Research has initiated coverage on Sagility India Ltd., noting the healthcare services provider’s strong positioning as a leading US-focused business process management firm, with domain expertise.

India’s healthcare sector is expected to reach $320 billion by 2028, Great Place To Work said in its latest report on the pharmaceuticals, healthcare, and biotechnology sectors. The pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year, the report added.

International expansion, talent driving growth
Over the past year, the pharmaceuticals, healthcare, and biotechnology industries have gone through major transformation. Major trends observed include:

1. International expansion: Robust growth in exports and partnerships.
2. Industry consolidation: Mergers and acquisitions driving efficiency.
3. Investment in talent: Leveraging India’s skilled workforce to power innovation.

The Great Place To Work report also found that firms are doubling down on employee development, leadership grooming, and strategic talent retention, aligning workforce goals with technological advancements like artificial intelligence (AI).

Employee development at the forefront
Commenting on industry trends, Balbir Singh, executive director & CEO of Great Place To Work, India, said, “The pandemic accelerated innovation, but the marathon continues. With healthcare AI investments expected to hit $1.6 billion by 2025, India is not just advancing science but also creating dynamic workplaces that nurture talent.”

Singh further noted that 85 per cent of employees at India’s Best Workplaces believe their organisations are great, rising to 89 per cent among top-ranked companies. A significant 85 per cent of these workplaces also invested in employee development plans this year, compared to 73 per cent last year.

Sector-specific challenges
Pharmaceuticals
Pharma companies excelled in mentorship, skill enhancement, and performance-based progression this year. However, the report noted that leveraging AI tools, transparent decision-making, and tailored training could further enhance productivity. Leadership programmes and inclusivity-focused mobility initiatives are also vital to growth.

Healthcare
Healthcare companies meanwhile are leveraging technology and flexible work models to drive efficiency. Key improvements include competency-based hiring and equitable recruitment from underrepresented regions. Continuous learning opportunities, including e-learning and specialised training have been noted as critical for sustained growth in the industry.

Biotechnology
Biotech firms thrived on rotational training, upskilling, and hands-on certifications. However, to sustain growth, companies need more inclusive hiring, personalised onboarding with leadership support, and career-specific academies. Transparent recognition initiatives and structured performance evaluations may also help retain talent. Business Standard

Billionaire Mukesh Ambani’s Reliance Industries has acquired technology-driven and oncology-focused healthcare platform Karkinos for Rs 375 crore, the firm said on Saturday.

Reliance Strategic Business Ventures (RSBVL), a wholly-owned subsidiary of Mumbai-listed India’s most valuable company, completed the acquisition of Karkinos Healthcare Pvt Ltd with allotment of requisite shares, the firm said in a stock exchange filing.

Karkinos was incorporated in India on July 24, 2020, and is in the business of providing technology-driven innovative solutions for the early detection, diagnosis, and management of cancer. It had a turnover of about Rs 22 crore in the 2022-23 fiscal.

“Reliance Strategic Business Ventures Ltd has on December 27, 2024, subscribed to and has been allotted 10 mn equity shares of Rs 10 each, for cash, aggregating Rs 10 crore and 365 million optionally fully convertible debentures of Rs 10 each, for cash, aggregating Rs 365 crore of Karkinos,” according to the filing.

Karkinos, it said, has cancelled the existing outstanding 30,075 equity shares held by the erstwhile shareholders of the company in accordance with the approved resolution plan.

It, however, did not give details.

Its previous prominent investors included Ewart Investments Limited (100 per cent subsidiary of Tata Sons), Reliance Digital Health Ltd (a subsidiary of Reliance Industries), Mayo Clinic (US), Sundar Raman (Director at Reliance Foundation Youth Sports and former COO of Indian Premier League since 2008), and Ravi Kant (ex-MD of Tata Motors).

The company is focused on providing end-to-end services relating to early detection and effective treatment of cancer at substantially lower than prevailing rates, while still generating healthy profitability. In order to meet this vision, Karkinos started partnering with hospitals to provide oncology services (testing, radiation therapy, etc.).

The company has partnered with around 60 hospitals till December 2023. It is through a subsidiary setting up a 150-bed multispecialty cancer hospital at Imphal, Manipur. Going forward, its source of income was said to be via Advanced Cancer Care Diagnostics and Research (ACCDR), Distributed Cancer Care Network (DCCN), tie-ups with corporates for early diagnosis of cancer, and cancer care hospitals.

“The acquisition of Karkinos will help expand the health services business portfolio of the Reliance group,” the filing said.

The resolution plan for Karkinos was approved by the National Company Law Tribunal (NCLT), Mumbai Bench, and no additional governmental or regulatory approvals were needed for the transaction, it added.

Earlier, on December 10, Reliance announced that the NCLT had approved the resolution plan submitted by RSBVL for Karkinos under the Corporate Insolvency Resolution Process of the Insolvency and Bankruptcy Code, 2016. PTI